Wegovy BMI requirements explained (NHS and private)

Simon Edward • 22 August 2025

Curious about the Wegovy BMI requirements? Discover the BMI cutoff for access to Wegovy through the NHS or private care.



Curious about the Wegovy BMI requirements? Discover the BMI cutoff for access to Wegovy through the NHS or private care.

If you're thinking about starting weight loss treatment with Wegovy, one of the first things you'll need to check is whether you meet the BMI requirements.


Body mass index (BMI) is a simple calculation that uses your weight and height to estimate your body fat. It's far from perfect, but it's the most widely used tool for assessing eligibility for GLP-1 weight loss medication in both NHS and private care.

Here's what you need to know about Wegovy BMI requirements and how to get started safely.


NHS vs private: key differences in BMI cutoffs for treatment

Wegovy is available through both the NHS and private providers like SemaPen, but the BMI requirements aren't the same. Here's a quick breakdown.


BMI requirement Weight-related health condition is required Access pathway
NHS At least 35 (or 30–34.9 plus extra criteria) Yes GP first, then referral to a specialist
Private (e.g. SemaPen) At least 30 (or 27–29.9 with related health condition) Yes (if BMI 27-29.9) Private medical assessment

NHS access to Wegovy: stricter criteria and a slower process

Wegovy became available through the NHS UK for weight loss in September 2023, but GPs don't prescribe it directly. People must be referred to specialist weight management services to access Wegovy.

To qualify, patients generally need:

  • A BMI of 35 or more
  • A weight-related health condition, such as type 2 diabetes, high cholesterol or sleep apnoea
  • Documented attempts to lose weight through lifestyle changes
  • To be willing to follow a multidisciplinary weight-loss plan that includes diet and exercise

In some cases, people with a BMI between 30 and 34.9 may qualify if they have a significant obesity-related condition. A person's ethnic background may also be taken into account, since people from certain groups may experience health risks at a lower BMI.


The NHS criteria are designed to ensure that those at most risk receive support. But the process can be lengthy, and many people face long wait times for assessment and treatment.


Picture of hospital waiting room.

For full details, please see the official NHS guidance.

Private access: broader criteria and faster access to care

Private providers can prescribe Wegovy to a wider group of people. While the same medication is used, the process is more flexible and designed around your individual health status, not your local referral system.

You may be eligible for Wegovy privately if:

  • Your BMI is 30 or higher
  • Your BMI is between 27 and 29.9, and you have a related condition such as prediabetes, insulin resistance, high blood pressure or high cholesterol

As with the NHS criteria, a person's ethnic background is also considered.

At SemaPen, every patient completes a secure online health assessment reviewed by a licensed UK prescriber. If your BMI is in the lower range, your medical history will be evaluated to make sure semaglutide is safe and appropriate for you. This includes checking for medications that might interact and any conditions that could affect treatment.

There's no need for a GP referral. Instead, access is based on your needs and your eligibility.

SemaPen: your path to safe, supported weight loss

Do you meet the BMI criteria and want to explore semaglutide safely and effectively? Our team of obesity specialists is here to help. SemaPen's expert-led medical weight loss plans combine prescription access with remote monitoring, smart scales and compassionate support.

We make it easy to:

  • Check your eligibility quickly online
  • Get reviewed by a licensed UK prescriber
  • Access the right GLP-1 medication for you, whether that's Wegovy (semaglutide) or Mounjaro (tirzepatide)
  • Stay supported with regular check-ins and smart tracking

Are you ready to take the next step on your weight loss journey, with expert support focused on your goals? You can get started today by taking our online health assessment. Our specialists will review your answers and recommend a tailored treatment for you.

Sources

1. DHSC Media Team (2024) Accessing Wegovy for weight loss: Everything you need to know. GOV.UK. Retrieved from https://healthmedia.blog.gov.uk/2023/09/04/accessing-wegovy-for-weight-loss-everything-you-need-to-know/

This article was reviewed and approved by Alice Fletcher, Lead Bariatric Dietitian, on 31 July 2025.


A recent article suggested Wegovy and Mounjaro cause muscle loss equivalent to 10 years of ageing.

Can Wegovy and Mounjaro really cause 10 years of muscle loss?

by Simon Edward • 5 January 2026
A recent article suggested Wegovy and Mounjaro cause muscle loss equivalent to 10 years of ageing. Is that true? Get the full facts in our guide.
Discover why weight loss naturally slows over time, and learn how to move past plateaus

Why is weight loss not linear?

by Simon Edward • 29 December 2025
Discover why weight loss naturally slows over time, and learn how to move past plateaus with confidence.
Learn about the main clinical trials for Wegovy (semaglutide), including STEP, SURMOUNT, FLOW

What we learned from the Wegovy clinical trials

by Simon Edward • 26 December 2025
Learn about the main clinical trials for Wegovy (semaglutide), including STEP, SURMOUNT, FLOW and ESSENCE.
Trulicity is not an approved treatment for weight loss, but Wegovy and Mounjaro are effective

Can you take Trulicity injections for weight loss?

by Simon Edward • 22 December 2025
Trulicity is not an approved treatment for weight loss, but Wegovy and Mounjaro are effective and approved alternatives. Learn more in our guide.
What, exactly, is class 3 obesity? What about class 1 and class 2? Learn about the different obesity

What is class 3 obesity? The different obesity classes explained

by Simon Edward • 20 December 2025
What, exactly, is class 3 obesity? What about class 1 and class 2? Learn about the different obesity classes and what they mean for our health.
Body aches aren't listed as a side effect of Wegovy.

Got body aches on Wegovy? Here's what might be to blame

by Simon Edward • 15 December 2025
Body aches aren't listed as a side effect of Wegovy. So, why do so many people report feeling achy or tired? Join us as we explore the facts.
Most adults should eat 600 fewer calories per day to lose weight. But there's more to weight loss

What should my caloric intake be for weight loss?

by Simon Edward • 8 December 2025
Most adults should eat 600 fewer calories per day to lose weight. But there's more to weight loss than calories alone. Learn why in our guide.
You might have heard that Mounjaro is linked with depression and anxiety. Let's look at the facts

Can Mounjaro cause depression?

by Simon Edward • 5 December 2025
You might have heard that Mounjaro is linked with depression and anxiety. Let's look at the facts behind the claims.
Did you know that people living with obesity are more likely to be smokers? Let's explore the links

Can smoking cause obesity?

by Simon Edward • 4 December 2025
Did you know that people living with obesity are more likely to be smokers? Let's explore the links between smoking and body weight.
Mazdutide is a GLP-1 injection that works similarly to Mounjaro. Discover everything you need

Mazdutide from Lilly: a new Mounjaro alternative?

by Simon Edward • 1 December 2025
Mazdutide is a GLP-1 injection that works similarly to Mounjaro. Discover everything you need to know about this up-and-coming weight loss drug.
More posts